Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How The Prostate Cancer Market Will Look Over Next Decade

Executive Summary

As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.

You may also be interested in...



Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Prostate Cancer Approaches, Treatment Evolve In Asia Amid Wider Therapy Shifts

While multiple new approaches and drugs are being developed for different stages of prostate cancer globally, many remain unavailable across Asia Pacific markets, despite a rising overall incidence of the disease. Two specialists recently shared with Scrip their views on treatment issues and optimum approaches in this fast-changing environment, and how they see the broader role of existing and new therapies developing given recent clinical results and practice.

J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology

Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100290

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel